KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBT Margin (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed EBT Margin for 7 consecutive years, with 37.16% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 6732.0% year-over-year to 37.16%, compared with a TTM value of 6.04% through Dec 2025, down 458.0%, and an annual FY2025 reading of 5.17%, up 1040.0% over the prior year.
  • EBT Margin was 37.16% for Q4 2025 at Esperion Therapeutics, up from 36.66% in the prior quarter.
  • Across five years, EBT Margin topped out at 42.29% in Q1 2024 and bottomed at 1140.0% in Q1 2021.
  • Average EBT Margin over 5 years is 216.75%, with a median of 151.63% recorded in 2023.
  • The sharpest move saw EBT Margin surged 313267bps in 2021, then crashed -24628bps in 2022.
  • Year by year, EBT Margin stood at 448.4% in 2021, then skyrocketed by 33bps to 302.06% in 2022, then soared by 41bps to 178.06% in 2023, then soared by 83bps to 30.16% in 2024, then soared by 223bps to 37.16% in 2025.
  • Business Quant data shows EBT Margin for ESPR at 37.16% in Q4 2025, 36.66% in Q3 2025, and 16.25% in Q2 2025.